Most EBV-related Hodgkin (HL) and non-Hodgkin lymphomas (NHL) as well as epithelial malignancies are latency II, (EBNA-1, LMP-1-2, EBER, BART-miRs), which rely on both EBV genes and somatic mutations to drive tumour growth (211). Here, PDLIM7 is linked to neoplasm.